Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
AIDS Res Hum Retroviruses
; 36(5): 399-405, 2020 05.
Article
em En
| MEDLINE
| ID: mdl-31891665
ABSTRACT
We assessed bone mineral density (BMD) in a cohort of human immunodeficiency virus (HIV)-positive patients after a median of 11 years of combination antiretroviral therapy (cART) and evaluated the respective role of HIV infection and antiretroviral drugs (ARVs). A cross-sectional study of 162 participants (131 male) from the ANRS-C08 cohort was performed with bone dual-energy X-ray absorptiometry (DXA) scans and renal assessment. The window of exposure to ARVs was defined as an exposure of more than six cumulative months during the last 3 years before the DXA evaluation to account for a cumulative exposure that could affect bone remodeling. The association with low BMD (Z-score < -2) was assessed by a multiple logistic regression model. The study population was 50 years (median), hepatitis C virus (HCV) (18%), and hepatitis B virus (HBV) (8%) coinfection with HIV-RNA <50 c/mL in 89%, median CD4 of 619/mm3. Prevalence of low BMD was 18% in males and 6% in females. The factors associated with a Z-score < -2 in males were uric acid renal loss [adjusted odds ratio (aOR) 6.1; 95% confidence interval (CI) 1.2-31.5; p = .03], HCV coinfection (aOR 4.0; 95% CI 1.3-12.2; p = .02), and less frequent window of exposure to nevirapine (NVP) (aOR 0.1; 95% CI 0.02-0.6; p = .01). For the full study sample, there was a strong positive association between duration of exposure to NVP and lumbar spine Z-score (p = .004). HIV-positive patients exposed to long-term cART have a high incidence of low BMD. Tenofovir disoproxil fumarate and ritonavir-boosted protease inhibitors did not seem to be associated with increased risk of low BMD, whereas NVP exposure appeared to have an independent positive association.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Densidade Óssea
/
Infecções por HIV
/
Inibidores da Transcriptase Reversa
/
Nevirapina
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article